
Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Results of the Phase III AENEAS trial, to be presented at ASCO 2021, demonstrate better efficacy and improved tolerability, including less frequent rash and diarrhea, […]
